Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 417
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 148
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
Charles E. Hendrick, Jeff R. Jorgensen, Charu Chaudhry, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 7, pp. 1182-1190
Open Access | Times Cited: 96
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 92
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76
New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective**
Ulrich Lücking
Chemistry - A European Journal (2022) Vol. 28, Iss. 56
Closed Access | Times Cited: 69
Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality
Zhenyi Hu, Po‐Han Chen, Wenxue Li, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 7, pp. 4045-4055
Closed Access | Times Cited: 51
Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation
Ryan P. Wurz, Huan Rui, Ken Dellamaggiore, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 51
CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16
Andrea G. Shergalis, Violeta L. Marin, David Y. Rhee, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 2, pp. 331-339
Closed Access | Times Cited: 47
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 27
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor
Valentina Scabia, Ayyakkannu Ayyanan, Fabio De Martino, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 67
PROTAC degraders as chemical probes for studying target biology and target validation
Václav Nêmec, Martin P. Schwalm, Susanne Müller, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 18, pp. 7971-7993
Closed Access | Times Cited: 51
Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors
Liwen Hua, Qiuyue Zhang, Xinyue Zhu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 12, pp. 8091-8112
Closed Access | Times Cited: 47
PROTAC therapy as a new targeted therapy for lung cancer
Jennifer W. Li, Guangrong Zheng, Frederic J. Kaye, et al.
Molecular Therapy (2022) Vol. 31, Iss. 3, pp. 647-656
Open Access | Times Cited: 44
Protein Phosphatase 5-Recruiting Chimeras for Accelerating Apoptosis-Signal-Regulated Kinase 1 Dephosphorylation with Antiproliferative Activity
Qiuyue Zhang, Xuexuan Wu, Hengheng Zhang, et al.
Journal of the American Chemical Society (2022) Vol. 145, Iss. 2, pp. 1118-1128
Closed Access | Times Cited: 40
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 25
The importance of binding kinetics and drug–target residence time in pharmacology
Kevin E. Knockenhauer, Robert A. Copeland
British Journal of Pharmacology (2023) Vol. 181, Iss. 21, pp. 4103-4116
Closed Access | Times Cited: 24
Ce6 nanoassemblies: Molecular mechanism and strategies for combinational anticancer therapy
Yuwei Liu, Shuting Xu, Qingyang Lyu, et al.
Aggregate (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 24
Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review
J Yang, Weijia Zhi, Lifeng Wang
Molecules (2024) Vol. 29, Iss. 12, pp. 2812-2812
Open Access | Times Cited: 13
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 11
EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling
Zhenyi Hu, Po‐Han Chen, Wenxue Li, et al.
Science Advances (2024) Vol. 10, Iss. 13
Open Access | Times Cited: 10
Luciferase- and HaloTag-based reporter assays to measure small-molecule-induced degradation pathway in living cells
Martin P. Schwalm, Krishna Saxena, Susanne Müller, et al.
Nature Protocols (2024) Vol. 19, Iss. 8, pp. 2317-2357
Closed Access | Times Cited: 8
Modulating the phosphorylation status of target proteins through bifunctional molecules
Qindi He, Zhijie Wang, Rongrong Wang, et al.
Drug Discovery Today (2025), pp. 104307-104307
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top